However, a recent study, which was performed based on pooled analysis using comprehensive data from 67 phase I to IV clinical trials of omalizumab in various indications, concluded that a causal relationship between omalizumab therapy and malignancy is unlikely.
Porén, un estudo recente, que foi realizado baseándose nunha análise combinada utilizando datos exhaustivos de 67 ensaios clínicos do omalizumab en fases I a IV en varias indicacións, concluíron que é improbable unha relación causal entre a terapia con omalizumab e a malignidade tumoral.